Migraine injection (typically sumatriptan) acts as a selective serotonin receptor (5-HT1B/1D) agonist that causes vasoconstriction of cranial blood vessels and inhibits pro-inflammatory neuropeptide release in the trigeminal system. By targeting these specific receptors, it effectively reduces neurogenic inflammation and interrupts the pain cascade associated with cluster headaches, providing rapid symptomatic relief.